Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

701.23 +18.30 (+2.68%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s
Eli Lilly stock has risen over 400% in 5 years despite a recent pullback. 
Via Talk Markets
This Is What Whales Are Betting On Eli Lilly
 
Via Benzinga
Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories. 
Via MarketBeat
Topics Artificial Intelligence
3 Profitable Stocks Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Via The Motley Fool
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady. 
Via Benzinga
Elon Musk-Led SpaceX Starlink Gets Final Regulatory Approval For Launch In India: Report
Reuters reported on Wednesday, citing three sources, that Starlink has cleared the only remaining regulatory hurdle for the satellite provider to enter the market. 
Via Stocktwits
FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction. 
Via Benzinga
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less... 
Via Stocktwits
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation. 
Via Stocktwits
Topics ETFs Economy Government
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025 
Via MarketBeat
Topics Economy World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes. 
Via Benzinga
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care. 
Via Benzinga
LVM Capital Management Loads Up on NOC, Buys 6,237 Shares in Q2 2025
LVM Capital Management bought a $3.16 million stake in Northrop Grumman last quarter. 
Via The Motley Fool
Topics Regulatory Compliance
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
Via The Motley Fool
Topics Regulatory Compliance
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
Via The Motley Fool
Topics Stocks
3 Underrated Dividend Growth Stocks to Buy and Hold for Years
Via The Motley Fool
Topics World Trade
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
 
Via Benzinga
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock. 
Via Benzinga
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns. 
Via Benzinga
Michael McTague: The pharmaceutical giants leading the market-cap parade in 2025
Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market capitalization has risen farthest? Whose 
Via Equities.com
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert
Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access. 
Via Benzinga
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Via The Motley Fool
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...'
Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery. 
Via Benzinga
Topics Artificial Intelligence
2 Stocks to Buy on the Dip and Hold for 10 Years
Via The Motley Fool
2 Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.